Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
NA
30 participants
INTERVENTIONAL
2023-01-25
2026-01-24
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Patch-free Occlusion Therapy
NCT05440448
Observation Versus Occlusion Therapy for Intermittent Exotropia
NCT01032330
Trial of Vision Therapy for Intermittent Exotropia
NCT04487249
Neurovascular Coupling in Subjects With Amblyopia
NCT01746693
Visual Cortex Stimulation in Patients With Amblyopia
NCT00097162
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Aim 2. OCT EF changes with foveation therapy.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
PARALLEL
TREATMENT
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Patching group
part-time patching following PEDIG guidelines.
eye patch
standard amblyopia treatment
foveation therapy
After-image foveation therapy training is 10 mins; MIT training is 5 minutes.
After-image and MIT trainer
Common clinical training for foveation
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
eye patch
standard amblyopia treatment
After-image and MIT trainer
Common clinical training for foveation
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. ocular causes of amblyopia that were identified as refractive(i.e., anisometropic, strabismus, or strabismic-anisometropic.
* Anisometropia included interocular difference of spherical equivalent \>=1D or interocular difference of astigmatism cylinder magnitude \>=1D;
* strabismus included those with deviation \>=10PD or good alignment after prior strabismus surgery;
* combined type included those who meet the criteria of both anisometropia and strabismus.
* For the patching group, we will enroll 15 children with strabismic amblyopia who are prescribed patching treatment. Age: 4-12 years old.
* For the foveation therapy group, we will enroll 15 children with strabismic amblyopia who are prescribed foveation therapies. Age: 8-16 years old.
Exclusion Criteria
* neurologic, developmental, or systemic illnesses known to be associated with ocular pathologies;
* congenital or acquired macular pathology.
4 Years
16 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
State University of New York College of Optometry
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Jingyun Wang
Associate Professor
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Jingyun Wang
Role: PRINCIPAL_INVESTIGATOR
SUNY College of Optmetry
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
SUNY College of Optometry
New York, New York, United States
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Jingyun Wang
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
1912342
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.